Vaccine-focused Valneva confirms
Valneva SE, a vaccine-focused biotech company, has confirmed that its vaccine against COVID-19 has shown promising results in clinical trials.
The company stated that its vaccine, called VLA2001, has demonstrated strong immunogenicity and safety in Phase 2 clinical trials, with results indicating that it is well-tolerated and effective in generating a robust immune response against the SARS-CoV-2 virus.
Valneva's CEO, Thomas Lingor, expressed confidence in the vaccine's potential, saying,
"We are excited about the Phase 2 results of our COVID-19 vaccine candidate VLA2001. The data suggests that our vaccine is safe, well-tolerated, and immunogenic, and we believe it has the potential to play an important role in the fight against COVID-19."
Valneva plans to proceed with Phase 3 clinical trials, which will further assess the vaccine's safety and efficacy in a larger population.
Resumen: El CEO de Valneva, Thomas Lingor, ha expresado su confianza en la vacuna, afirmando que "estamos emocionados con los resultados de la fase 2 de nuestra candidata de vacuna contra el COVID-19, VLA2001. Los datos sugieren que nuestra vacuna es segura, bien tolerada e inmunógena, y creemos que tiene el potencial de desempeñar un papel importante en la lucha contra el COVID-19."
More News
- Leonardo DiCaprio's stepmom and dad steal the show
- College Football Playoff Rankings LIVE SHOW | Reveal …
- 3 Million for One Day… Yet DiCaprio Said No: The Actor Refuses the Most Anticipated Sequel of His Career
- Leonardo – Shaping the Future of Global Security and Innovation
- Leonardo DiCaprio Steps Out With Dad and Stepmom in Rare Appearance
- George Russell conseille Max Verstappen : « Il n'est pas nécessaire de piloter comme un voyou »
- George Russell: Older me can’t envy Lando Norris’ F1 title, he deserves it
- Russell assesses Mercedes’ chance of sealing P2 in Abu Dhabi
- Leonardo DiCaprio – biographie
- George Russell Stuns Title Contenders to Top Decisive FP3